Cat. No. 3422
Biological ActivityBombesin receptor antagonist that inhibits bombesin binding to rat brain with an IC50 value of 2 μM. Inhibits amylase release in vitro (IC50 = 4 μM) and attenuates bombesin-mediated suppression of food intake in vivo.
(Modifications: X = Glp, Phe-12 = D-Phe, Leu-14 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Flynn (1997) Bombesin receptor antagonists block the effects of exogenous bombesin but not of nutrients on food intake. Physiol.Behav. 62 791. PMID: 9284499.
Merali et al (1988) (d-Phe12) bombesin and substance P analogues function as central bombesin receptor antagonists. Synapse 2 282. PMID: 2463692.
Heinz-Erian et al (1987) [d-Phe12]bombesin analogues: a new class of bombesin receptor antagonists. Am.J.Physiol. 252 G439. PMID: 2435173.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses [D-Phe12,Leu14]-Bombesin from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: [D-Phe12,Leu14]-Bombesin, supplier, Bombesin, receptor, antagonists, GRP-Preferring, Receptors, BB1, BB2, BB3, Gastrin-Releasing, Peptide-Preferring, NMB-Preferring, Neuromedin, B-Preferring, Tocris Bioscience, Bombesin Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
April 1 - 5, 2017
Washington, D.C., USA